Thymalin
Thymalin; polypeptide extract of calf thymus (containing active dipeptides EW [Glu-Trp, 'thymogen'] and KE [Lys-Glu], and tripeptide EDP [Glu-Asp-Pro, 'crystagen'])
Human data is very limited. Most evidence comes from case reports or observational studies.
A natural extract from thymus gland tissue containing short peptides that support immune function, particularly the development of T-cells (immune cells that fight infection and cancer). Small studies in elderly COVID-19 patients showed faster immune recovery compared to standard care alone.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Clinical trial literature and medical summaries describe thymalin as well tolerated with 'practically no side effects.' No consistent acute adverse events, published event-frequency tables, dose-limiting toxicities (DLTs), or maximum tolerated dose (MTD) have been reported in publicly available clinical literature (PMC8365293, PMC8654498, Pillintrip thymalin listing). Pharmacovigilance searches of FAERS, EudraVigilance, and WHO VigiBase returned no specific safety signals attributable to thymalin. No CYP enzyme interactions documented. No anti-drug antibody formation reported. Systematic reviews of thymic peptides (Cochrane/Wolf et al. 2011, PMC6481824) report generally favorable profiles. No tolerance, tachyphylaxis, or withdrawal effects reported. CRITICAL DATA GAPS: No formal preclinical chronic/subchronic toxicology studies with NOAEL/LOAEL, no carcinogenicity/genotoxicity reports, no reproductive/developmental toxicity studies, and no dedicated PK studies in renal or hepatic impairment are publicly available. The 'clean' safety profile should be interpreted with caution as it likely reflects absence of rigorous safety monitoring rather than proven safety. Trials were small, unblinded, and may have underreported events. Community reports on and online communities generally report minimal side effects.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]